SS-31 Update: FDA Approval of Forzinity Changes the Elamipretide Story
James MitchellMSc Biochemistry The Current Regulatory Story
The most important current SS-31/elamipretide update is regulatory: FDA approved Forzinity (elamipretide) on September 19, 2025 for Barth syndrome under accelerated approval.
Forzinity is the clinical elamipretide product. It should not be treated as equivalent to research-channel “SS-31” listings.
What FDA Approved
FDA’s Drug Trials Snapshot says Forzinity is a mitochondrial cardiolipin binder indicated to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. FDA approved it under the accelerated approval program, which means continued approval may depend on confirmatory evidence.
This is a narrow, serious rare-disease approval. It is not a general longevity, anti-aging, or performance indication.
What the Trial Program Showed
FDA describes the pivotal evidence as a randomized, double-blind, placebo-controlled crossover trial and a long open-label extension. The trial enrolled 12 male patients with Barth syndrome at a single US site.
Key points for readers:
- The evidence base is small because Barth syndrome is ultra-rare.
- FDA’s approved indication centers on muscle strength, not broad mitochondrial wellness.
- Injection-site reactions are a known practical issue in the clinical program.
- Approval does not validate non-prescription research products sold online.
What This Means for Peptide Research Coverage
SS-31/elamipretide is one of the stronger examples of a peptide moving from research interest into regulated medicine. But the boundary matters:
- Forzinity is the FDA-approved medicine for a defined Barth syndrome population.
- SS-31 research products are not FDA-approved consumer products.
- Claims about aging, athletic performance, or general mitochondrial enhancement remain outside the approved label.
PeptideUnicorn will keep the SS-31 profile focused on the approved Barth syndrome context, the clinical evidence base, and the difference between regulated medicine and research-channel listings.
Sources
- FDA Drug Trials Snapshot: Forzinity
- FDA Novel Drug Approvals for 2025
- FDA integrated review for Forzinity
- TAZPOWER trial publication